UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 3, 2019
Trovagene, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
001-35558
|
27-2004382
|
|
(State or other jurisdiction
|
(Commission File Number)
|
IRS Employer
|
|
of incorporation or organization)
|
|
Identification No.)
|
11055 Flintkote Avenue
San Diego, CA 92121
(Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 952-7570
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
|
Common Stock
|
|
TROV
|
|
Nasdaq Capital Market
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
On September 3, 2019, Trovagene, Inc. issued a press release announcing it will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference at 10:50 a.m. Eastern time on Tuesday, September 10, 2019. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 3, 2019
|
|
|
|
|
|
|
|
TROVAGENE, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Thomas Adams
|
|
|
|
Thomas Adams
|
|
|
|
Chief Executive Officer
|
Trovagene to Present at the H.C. Wainwright 21st Annual Global Investment Conference
SAN DIEGO (September 3, 2019) – Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, today announced it will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference at 10:50 a.m. Eastern time on Tuesday, September 10, 2019. The conference is being held September 8-10, 2019 at the Lotte New York Palace Hotel.
Dr. Thomas Adams, Chief Executive Officer and Chairman, and Dr. Mark Erlander, Chief Scientific Officer of Trovagene, will provide an overview of the Company's business during the live presentation and will be available for one-on-one meetings with investors.
Institutional investors who would like to attend the company's presentation should click here to register for the conference. Once registered, you can log into the conference website to request a one-on-one meeting.
The presentation will be webcast live. To access the webcast, please click here. The webcast replay will remain available for 90 days following the live presentation.
About Trovagene, Inc.
Trovagene is a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemias, lymphomas and solid tumors. Trovagene has intellectual property and proprietary technology that enables the Company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics. For more information, please visit https://www.trovageneoncology.com.
Trovagene Contact:
Vicki Kelemen
VP, Clinical Development and Investor Relations
858-952-7652
vkelemen@trovagene.com
Trovagene Inc. | 11055 Flintkote Avenue | San Diego | CA 92121 | Tel.: USA [+1] 888-391-7992
